

Lyme Disease Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

Market Report | 2024-12-09 | 130 pages | Global Market Insights

AVAILABLE LICENSES:

- Single User \$4850.00
- Multi User \$6050.00
- Enterprise User \$8350.00

Report description:

The Global Lyme Disease Testing Market is expected to reach USD 6.7 billion in 2024 and is projected to grow at a CAGR of 5.7% from 2025 to 2034. This growth is primarily driven by the increasing prevalence of Lyme disease in regions like North America and parts of Europe, where the infection is most common. Rising awareness of the serious long-term effects of untreated Lyme disease, such as neurological and musculoskeletal complications, has fueled the demand for early diagnosis and prompt treatment, further expanding the market.

Significant advancements in diagnostic technologies, including the widespread adoption of point-of-care (POC) tests and at-home testing kits, are reshaping the market. These innovative solutions offer quick and convenient diagnostic options that promote early detection and intervention, encouraging individuals to take action sooner. Public health initiatives and educational campaigns supported by government and health organizations have been crucial in raising awareness and advocating for regular testing. Additionally, the growing funding for research on tick-borne diseases is driving innovation and fueling further growth within the market.

In terms of diagnostic technology, the market is divided into several segments, including serological tests, nucleic acid tests, lymphocytic transformation tests, urine antigen testing, and immunofluorescent staining. The serological test segment is poised to experience the highest growth, with a projected CAGR of 6.2%, generating USD 5 billion by 2034. This growth is primarily attributed to the increasing adoption of serological tests, driven by technological advancements that have enhanced their reliability and effectiveness. Tests such as enzyme-linked immunosorbent assay (ELISA) and Western blot are highly effective at detecting *Borrelia burgdorferi* antibodies, securing their position as the most widely used and trusted method for Lyme disease detection.

The market is also categorized by sample type, including blood, urine, cerebrospinal fluid (CSF), and other blood-based samples. In 2024, the blood sample segment accounted for a 52.2% share of the market and is expected to maintain its dominant position

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

throughout the forecast period. Blood samples are considered the gold standard for Lyme disease testing due to their high accuracy in detecting both antibodies and bacterial DNA. This makes them the preferred choice in clinical and laboratory settings, offering a simple and non-invasive diagnostic method.

In the U.S., the Lyme disease testing market, valued at USD 2.6 billion in 2024, is poised for strong growth during the forecast period. The high incidence of Lyme disease, combined with its geographical spread due to climate change and increased tick activity, is driving demand for testing services. Growing public awareness, supported by health organizations, is encouraging more proactive approaches to Lyme disease screening. As a result, healthcare providers are increasingly prioritizing Lyme disease testing, especially in high-risk areas, contributing to sustained market growth in the region.

Table of Contents:

Report Content

Chapter 1Methodology and Scope

1.1Market scope and definitions

1.2Research design

1.2.1Research approach

1.2.2Data collection methods

1.3Base estimates and calculations

1.3.1Base year calculation

1.3.2Key trends for market estimation

1.4Forecast model

1.5Primary research and validation

1.5.1Primary sources

1.5.2Data mining sources

Chapter 2Executive Summary

2.1Industry 360 synopsis

Chapter 3Industry Insights

3.1Industry ecosystem analysis

3.2Industry impact forces

3.2.1Growth drivers

3.2.1.1Increasing prevalence of Lyme disease

3.2.1.2Advancements in diagnostic technologies

3.2.1.3Rising adoption of at-home test kits

3.2.1.4Growth in point-of-care testing

3.2.1.5Integration of artificial intelligence (AI)

3.2.2Industry pitfalls and challenges

3.2.2.1High cost of advanced diagnostic tests

3.2.2.2Lack of standardized testing guidelines

3.3Growth potential analysis

3.4Regulatory landscape

3.5Reimbursement scenario

3.6Technology landscape

3.7Gap analysis

3.8Porter's analysis

3.9PESTEL analysis

- 3.10 Value chain analysis
- Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
- Chapter 5 Market Estimates and Forecast, By Diagnostic Technology, 2021 - 2034 (\$ Mn)
- 5.1 Key trends
- 5.2 Serological test
 - 5.2.1 ELISA
 - 5.2.2 Western blot
- 5.3 Nucleic acid test
- 5.4 Urine antigen testing
- 5.5 Lymphocytic transformation test
- 5.6 Immunofluorescent staining
- Chapter 6 Market Estimates and Forecast, By Sample Type, 2021 - 2034 (\$ Mn)
- 6.1 Key trends
- 6.2 Blood
- 6.3 Urine
- 6.4 CSF
- 6.5 Other blood samples
- Chapter 7 Market Estimates and Forecast, By Patient Type, 2021 - 2034 (\$ Mn)
- 7.1 Key trends
- 7.2 Adult
- 7.3 Pediatric
- Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 (\$ Mn)
- 8.1 Key trends
- 8.2 Hospitals
- 8.3 Diagnostic laboratories
- 8.4 Other end use
- Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 (\$ Mn)
- 9.1 Key trends
- 9.2 North America
 - 9.2.1 U.S.
 - 9.2.2 Canada
- 9.3 Europe
 - 9.3.1 Germany
 - 9.3.2 UK
 - 9.3.3 France
 - 9.3.4 Spain
 - 9.3.5 Italy
 - 9.3.6 Netherlands
- 9.4 Asia Pacific
 - 9.4.1 China
 - 9.4.2 Japan

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.5 Latin America
 - 9.5.1 Brazil
 - 9.5.2 Mexico
 - 9.5.3 Argentina
- 9.6 Middle East and Africa
 - 9.6.1 South Africa
 - 9.6.2 Saudi Arabia
 - 9.6.3 UAE
- Chapter 10 Company Profiles
 - 10.1 bioMerieux
 - 10.2 Bio-Rad Laboratories
 - 10.3 Ceres Nanosciences
 - 10.4 DiaSorin
 - 10.5 Galaxy Diagnostics
 - 10.6 Gold Standard Diagnostics
 - 10.7 IGeneX
 - 10.8 Oxford Immunotec
 - 10.9 T2 Biosystems
 - 10.10 Thermo Fisher Scientific
 - 10.11 Trinity Biotech
 - 10.12 ZEUS Scientific

Lyme Disease Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

Market Report | 2024-12-09 | 130 pages | Global Market Insights

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4850.00
	Multi User	\$6050.00
	Enterprise User	\$8350.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-12"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com